Genworth Financial (GNW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Strategy centers on value creation through Enact market value, capital returns, and growth in CareScout's aging care services and funding solutions.
Board oversight ensures disciplined execution, capital allocation, and risk management.
Significant capital returns, share repurchases, and new product launches marked 2025.
Cumulative total shareholder return outperformed industry peers since 2020.
Forward-looking statements highlight ongoing investments, share repurchases, and new business lines.
Voting matters and shareholder proposals
Election of ten directors, advisory vote on executive compensation, and approval of the 2026 Associate Stock Purchase Plan are on the agenda.
Ratification of KPMG as independent registered public accounting firm.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board is 90% independent with an independent Non-Executive Chair.
Five new directors added since 2021; board effectiveness supported by annual self-assessments.
Governance best practices include majority voting, non-classified board, and 25% special meeting threshold.
Board oversees strategy, capital allocation, risk, and CEO succession planning.
Technology Committee established; board refreshment aligned with strategic needs.
Latest events from Genworth Financial
- Shareholders to vote on directors, pay, stock plan, and auditor amid strong performance and governance.GNW
Proxy filing6 Apr 2026 - Key votes include director elections, executive pay, stock plan, and auditor ratification.GNW
Proxy filing6 Apr 2026 - Proxy details 2025 performance, capital returns, and key votes on directors, pay, and auditor.GNW
Proxy filing24 Mar 2026 - Enact drove Q4 profits and capital returns; CareScout expanded as LTC losses weighed on results.GNW
Q4 202524 Feb 2026 - Q2 2024 adjusted operating income rose to $125M, driven by Enact and strong capital returns.GNW
Q2 20242 Feb 2026 - Q3 net income rose to $85M, driven by Enact strength, LTC actions, and CareScout growth.GNW
Q3 202415 Jan 2026 - Q1 2025 net income was $54M, driven by Enact, CareScout growth, and capital returns.GNW
Q1 202523 Dec 2025 - Q4 net loss of $1M, strong Enact results, and $565M in share repurchases amid LTC headwinds.GNW
Q4 202421 Dec 2025 - Shareholders to vote on board, pay, incentive plan, auditor, and governance changes after a strong year.GNW
Proxy Filing1 Dec 2025